Trial Profile
A retrospective study analysing efficacy of Eculizumab with immunosuppresive therapy in patients with concurrent paroxysmal nocturnal hemoglobinuria and aplastic anemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Sep 2016
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Aplastic anaemia; Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- 12 Sep 2016 New trial record